

Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference

May 7, 2019

EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will provide a corporate update at the Bank of America Merrill Lynch 2019 Healthcare Conference, being held in Las Vegas, NV, from May 14-16, 2019.

Presentation Details

Date: Tuesday, May 14, 2019
Time: 8:00 PM Eastern Time / 5:00 PM Pacific Time
Location: Las Vegas, NV - Encore Hotel

The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at <https://zogenixinc.gcs-web.com>.

About Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company's MAA for its lead candidate FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company's NDA. For more information, visit www.zogenix.com.

CONTACT:

Zogenix

Melinda Baker
Senior Director, Corporate Communications
media@zogenix.com

Media

Rachel Lipsitz
Public Relations, Syneos Health
+1 (858) 449 9575 | rachel.lipsitz@syneoshealth.com

Investors

Andrew McDonald
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com

The Zogenix logo features the word "ZOGENIX" in a bold, purple, sans-serif font. A green swoosh underline is positioned beneath the letters "O" and "G".

Source: Zogenix, Inc.